In 2023, the number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in the US stood at 130. Forecasts from 2024 to 2028 show an overall slight decline in cases. By 2028, projected cases are anticipated to decrease marginally to 128, indicating a relatively stable but slightly downward trend.
The year-on-year variation between 2024 and 2028 demonstrates minimal change, fluctuating between 129 and 130 cases annually. The Compound Annual Growth Rate (CAGR) over these five years highlights an insignificant average yearly decrease, suggesting that the prevalence of RR-/MDR-TB cases remains relatively constant.
Future trends to watch for include the potential impact of new medical advancements, public health initiatives targeting TB reduction, and broader socio-economic factors that could alter either an increase or further reduction in cases. Monitoring these elements will be crucial in anticipating changes in RR-/MDR-TB case prevalence.
